Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200 Day Moving Average – Here’s Why

Genmab A/S (OTCMKTS:GNMSF)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $305.26 and traded as low as $275.30. Genmab A/S shares last traded at $275.30, with a volume of 8 shares traded.

Genmab A/S Trading Down 5.1%

The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The company has a market capitalization of $16.95 billion, a price-to-earnings ratio of 17.78 and a beta of 0.92. The business’s 50 day simple moving average is $313.97 and its 200 day simple moving average is $305.26.

Genmab A/S (OTCMKTS:GNMSF) last announced its earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $3.10 by ($2.55). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.